Our Mission is to promote developments in clinical use of cord blood cells. We collaborate with public European CBB and registries and contribute to generation and validation of high quality data used in clinical research
First world success
First world success on Gene Therapy on Thalassemia The only available curative therapy is allogeneic haematopoietic stem cell transplantation, although most patients do not have a human-leukocyte-antigen-matched, geno-identical donor, and those who do still risk rejection or graft-versus-host disease. Here we show that, 33 months after lentiviral β-globin gene transfer, an adult patient with severe βE/β0-thalassaemia dependent on monthly transfusions since early childhood has become transfusion independent for the past 21 months.
Eurocord organization aims to promote the advancement of scientific academic and industrial research, the development of therapeutic applications and dissemination of knowledge related to the umbilical cord, placenta, annexes and more generally all that is within the field of materno-fetal interactions. The goal of Eurocord organization is to unite around the same project, researchers, biologists and clinicians working on stem cells derived from cord blood, placenta and its annexes, to promote national and international collaborations and disseminate knowledge in this field through its site eurocord.org.